BEDFORD, Mass., Nov. 3 /PRNewswire/ -- Insulet Corporation announced today that its OmniPod(R) Insulin Management System has won a Nixon Peabody/Smith & Nephew Medical Device Innovation Award from the Massachusetts Medical Device Industry Council (MassMEDIC). The OmniPod Insulin Management System is an innovative new product for the treatment of diabetes that brings together safe, reliable, continuous subcutaneous insulin delivery and blood glucose monitoring in an easy-to-use, two-part system with no tubing. This is the fourth innovation award Insulet has received this year.
“It is an honor to be recognized once again for the OmniPod Insulin Management System,” said Duane DeSisto, President and CEO, Insulet Corporation. “Through innovative design, we’ve created a safe, discreet, easy to use system that enables more people with insulin-dependent diabetes to take advantage of continuous subcutaneous insulin infusion therapy.”
The Nixon Peabody/Smith & Nephew Medical Device Innovation Award was established in 2005 to honor novel medical technologies that have demonstrated a positive outcome in the healthcare setting. Four winners and two honorable mentions will be honored at the MedTech Investors Conference on November 9th. Insulet Corporation is a co-winner with SuturTek, Inc. in the Early-Stage Company category. Other categories recognized emerging and established companies.
This is the fourth significant innovation and design award received by Insulet this year, including a Gold Industrial Design Excellence Award (IDEA) from the Industrial Designers Society of America (IDSA), a 2006 New England Innovation Award from the Smaller Business Association of New England (SBANE), and a Gold 2006 Medical Device Excellence Award from Canon Communications LLC.
Designers of the OmniPod System used innovative design and materials and overcame a number of technological challenges to create a system that has all the functionality of a conventional insulin pump with no tubing. Conventional insulin pumps are complex electromechanical devices that have hundreds of components and are connected to the body via an infusion set with up to 42 inches of tubing. With the OmniPod Insulin Management System, Insulet’s design team was able to separate the controls and user interface from the insulin delivery mechanism, eliminating the need for tubing.
The System consists of the handheld, wireless Personal Diabetes Manager (PDM) which programs the OmniPod with insulin delivery instructions and monitors its operation, and the compact, lightweight OmniPod, which is worn discreetly beneath clothing and delivers insulin based on instructions from the PDM. The PDM contains a fully integrated blood glucose meter and is very similar in materials, construction and appearance to a personal digital assistant. The OmniPod features an automated cannula insertion system designed to minimize the physical discomfort of insertion.
About MassMEDIC
The Massachusetts Medical Device Industry Council (MassMEDIC) was established in 1996 by medical device company executives interested in promoting the unique interests of the Bay State’s vibrant medical technology sector. MassMEDIC now has more than 300 members - manufacturers, product developers, suppliers, research institutions and academic health centers. The company advocates industry positions at the federal and state government levels, and conducts numerous informational seminars, conferences and issue briefings aimed at bringing the region’s medical device community the latest and best information on policies and trends impacting the sector. (www.massmedic.com)
About Insulet Corporation
Insulet Corporation, located in Bedford, Massachusetts, is an innovative, privately held, diabetes management company dedicated to designing and developing products that provide superior treatment options and lifelong health benefits to people with diabetes. Insulet Corporation employees have extensive experience in the diabetes and medical device industries. Founded in 2000, the company seeks to improve the lives of people with diabetes - and to break down the barriers to Continuous Subcutaneous Insulin Infusion (CSII) therapy - through innovative design and technology, and through feedback from people with diabetes, physicians, and diabetes educators. (www.insulet.com)
Insulet Corporation
CONTACT: Hugh Ryan of Ryan Wellnitz & Associates, +1-401-246-2300, orhryan@ryanwellnitz.com
